ArticleBMC musculoskeletal disorders2010
Anti-centromere antibody-seropositive Sjögren's syndrome differs from conventional subgroup in clinical and pathological study.
Article in BMC musculoskeletal disorders, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 45 citations in OpenAlex.
- Non-Conventional and Emerging Autoantibodies in Sjögren's Disease.Journal of inflammation research · 2026Review
- Case of successful treatment with glucocorticoid for isolated anti-centromere antibody-positive acute interstitial nephritis.CEN case reports · 2025Article
- Common pathological mechanisms and therapeutic strategies in primary Sjogren's syndrome and primary biliary cholangitis: from tissue immune microenvironment to targeted therapy.Frontiers in immunology · 2025Review
- Associations between metabolic disorders and Sjögren's disease.The Japanese dental science review · 2024Review
- Sjögren's syndrome positive for isolated anti-Ro52/SS-A antibody and anti-centromere antibody.The Journal of international medical research · 2024Article
- Ultrasound shear wave elastography for assessing minor salivary gland involvement in anti-centromere antibody-positive primary Sjögren's syndrome: a retrospective study.Clinical and experimental medicine · 2024Review
- Anti-centromere antibody positivity is an independent variable associated with salivary gland ultrasonography score in Sjögren's syndrome.Scientific reports · 2024Article
- Clinical influences of anticentromere antibody on primary Sjögren's syndrome in a prospective Korean cohort.The Korean journal of internal medicine · 2021Article
- Ultrasonographic characteristics of major salivary glands in anti-centromere antibody-positive primary Sjögren's syndrome.PloS one · 2021Article
- Association of Anticentromere Antibodies With More Severe Exocrine Glandular Dysfunction in Sjögren's Syndrome: Analysis of the Sjögren's International Collaborative Clinical Alliance Cohort.Arthritis care & research · 2016Article
- TLR3-mediated apoptosis and activation of phosphorylated Akt in the salivary gland epithelial cells of primary Sjögren's syndrome patients.Rheumatology international · 2013Article
- Serologic features of primary Sjögren's syndrome: clinical and prognostic correlation.International journal of clinical rheumatology · 2012Article
- Diagnostic Approaches to Sjögren's syndrome: a Literature Review and Own Clinical Experience.Journal of oral & maxillofacial research · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo clarify the clinicopathological characteristics of primary Sjögren's syndrome (pSS) with anti-centromere antibody (ACA).
methodsCharacteristics of 14 patients of pSS with ACA were evaluated. All patients were anti-SS-A/Ro and SS-B/La antibodies negative (ACA+ group) without sclerodactyly. The prevalence of Raynaud's phenomenon (RP), titer of IgG and focus score (FS) in the minor salivary glands (MSGs) were determined. Quantification analysis of Azan Mallory staining was performed to detect collagenous fiber. Forty eight patients in whom ACA was absent were chosen as the conventional (ACA-) pSS group.
resultsPrevalence of ACA+ SS patients was 14 out of 129 (10.85%) pSS patients. RP was observed in 61.5% of the patients with ACA. The level of IgG in the ACA+ group was significantly lower than that of the ACA- group (p = 0.018). Statistical difference was also found in the FS of MSGs from the ACA+ group (1.4 +/- 1.0) as compared with the ACA- group (2.3 +/- 1.6) (p = 0.035). In contrast, the amount of fibrous tissue was much higher in the ACA+ group (65052.2 +/- 14520.6 microm(2) versus 26251.3 +/- 14249.8 microm(2)) (p = 1.3 x 10(-12)).
conclusionsLow cellular infiltration but with an increase in fibrous tissues may explain the clinical feature of a high prevalence of RP and normal IgG concentration in ACA+ pSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.